| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P6179 | Dimensions Publication ID | 1024080709 |
| P356 | DOI | 10.1007/S10555-014-9540-2 |
| P932 | PMC publication ID | 4369418 |
| P698 | PubMed publication ID | 25544369 |
| P2093 | author name string | Lavakumar Karyampudi | |
| Purushottam Lamichhane | |||
| Claudia Preston | |||
| Keith L. Knutson | |||
| P2860 | cites work | Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan | Q24328949 |
| Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies | Q24619808 | ||
| The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 | ||
| Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women | Q24648412 | ||
| Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer | Q45289421 | ||
| Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer | Q46187608 | ||
| Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California | Q46329680 | ||
| Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas | Q46469890 | ||
| GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. | Q46490849 | ||
| Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study | Q46609744 | ||
| CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg | Q46631501 | ||
| IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells | Q46941757 | ||
| Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis | Q47347848 | ||
| NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. | Q47590599 | ||
| Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group | Q47701078 | ||
| Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study | Q47794474 | ||
| Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. | Q47812196 | ||
| CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. | Q47853213 | ||
| Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer | Q47968967 | ||
| Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer | Q50882577 | ||
| CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer | Q50955882 | ||
| High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels | Q51792647 | ||
| T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer | Q51935197 | ||
| Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer | Q51962005 | ||
| P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy | Q51976333 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma | Q53257187 | ||
| Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer | Q53285164 | ||
| Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. | Q53494978 | ||
| Mammaglobin B expression in human endometrial cancer | Q53515841 | ||
| The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. | Q35052176 | ||
| Natural versus adaptive regulatory T cells | Q35092554 | ||
| Interleukin-6 as a therapeutic target in human ovarian cancer | Q35239088 | ||
| Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer | Q35564007 | ||
| A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment | Q35656974 | ||
| Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study | Q35747569 | ||
| A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction | Q35787391 | ||
| Ovarian cancer risk associated with inherited inflammation-related variants | Q35802988 | ||
| Paraneoplastic thrombocytosis in ovarian cancer. | Q35812402 | ||
| Multiplicity and plasticity of natural killer cell signaling pathways | Q35849513 | ||
| Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer | Q35861249 | ||
| Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. | Q35988355 | ||
| Breast-feeding and risk of epithelial ovarian cancer | Q35991354 | ||
| Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. | Q36035342 | ||
| Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material | Q36046426 | ||
| Rethinking ovarian cancer: recommendations for improving outcomes | Q36050883 | ||
| Genital powder exposure and the risk of epithelial ovarian cancer | Q36062556 | ||
| Mechanisms of suppression by suppressor T cells | Q36078047 | ||
| Adoptive T cell therapy of solid cancers | Q36126116 | ||
| Tissue expression of PD-L1 mediates peripheral T cell tolerance. | Q36228541 | ||
| Role of folate receptor genes in reproduction and related cancers | Q36251010 | ||
| Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression | Q36259867 | ||
| Adoptive cell therapy for the treatment of patients with metastatic melanoma | Q36283034 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. | Q36376561 | ||
| Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites | Q36376598 | ||
| Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation | Q36388171 | ||
| Induction of ovulation and ovarian cancer: a critical review of the literature | Q36437389 | ||
| CD4 regulatory T cells in human cancer pathogenesis | Q36526954 | ||
| Dendritic cells and tumor microenvironment: a dangerous liaison | Q36569018 | ||
| Menstrual and reproductive factors in relation to ovarian cancer risk. | Q36622729 | ||
| Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. | Q36715028 | ||
| PD-1 and its ligands in T-cell immunity | Q36791446 | ||
| The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer | Q36802249 | ||
| High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma | Q24658024 | ||
| Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors | Q24673454 | ||
| Adoptive T cell therapy for cancer in the clinic | Q24680405 | ||
| Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer | Q24685406 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor | Q28118420 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis | Q28185207 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer | Q28220263 | ||
| Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer | Q28235980 | ||
| An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor | Q28249782 | ||
| Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor | Q28273769 | ||
| Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses | Q28283999 | ||
| Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer | Q28288802 | ||
| The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? | Q28295141 | ||
| Acute-phase proteins and other systemic responses to inflammation | Q28296941 | ||
| 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase | Q28333967 | ||
| A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. | Q29417084 | ||
| Common variants at 19p13 are associated with susceptibility to ovarian cancer | Q29417145 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 | ||
| Tumor angiogenesis | Q29614938 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Protective and pathogenic functions of macrophage subsets | Q29620351 | ||
| Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas | Q30310974 | ||
| SNPs, protein structure, and disease. | Q30328103 | ||
| Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | Q30670385 | ||
| Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls | Q31147531 | ||
| Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. | Q33217202 | ||
| HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients | Q33305210 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer | Q33389676 | ||
| Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer | Q33461888 | ||
| Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence | Q33487445 | ||
| Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors | Q33488520 | ||
| HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy | Q33517907 | ||
| Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target | Q33559560 | ||
| Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines | Q33566336 | ||
| Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival | Q33584997 | ||
| CA 125: the past and the future | Q33608456 | ||
| Innate IL-17-producing cells: the sentinels of the immune system | Q33608575 | ||
| Inherited determinants of ovarian cancer survival | Q33638923 | ||
| MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells | Q33638962 | ||
| The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs | Q33722537 | ||
| A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. | Q33747778 | ||
| Discovery of mesothelin and exploiting it as a target for immunotherapy | Q33772688 | ||
| Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer | Q33842859 | ||
| Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes | Q33933875 | ||
| Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. | Q33973463 | ||
| Principles of adoptive T cell cancer therapy | Q34003932 | ||
| A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer | Q34023737 | ||
| The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study | Q34025763 | ||
| Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells | Q34103579 | ||
| Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha | Q34111744 | ||
| Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer | Q34111817 | ||
| Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer | Q34122828 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase | Q34252356 | ||
| Expression of sperm protein 17 (Sp17) in ovarian cancer | Q34288730 | ||
| BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis | Q34299655 | ||
| C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). | Q34304775 | ||
| Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer | Q34333114 | ||
| The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. | Q34350624 | ||
| Markers of inflammation and risk of ovarian cancer in Los Angeles County | Q34372351 | ||
| Cancer of the ovary | Q34375262 | ||
| Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. | Q39333446 | ||
| "Incessant ovulation" and ovarian cancer | Q39559428 | ||
| IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer | Q39625091 | ||
| Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer | Q39741066 | ||
| Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors | Q39745133 | ||
| Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro | Q39768083 | ||
| Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma | Q39814919 | ||
| IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism | Q39991104 | ||
| Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity | Q40013431 | ||
| Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer | Q40019095 | ||
| MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer | Q40040185 | ||
| Overexpression of mammaglobin B in epithelial ovarian carcinomas | Q40162130 | ||
| Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference | Q40224792 | ||
| Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer | Q40236285 | ||
| CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells | Q40259796 | ||
| Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Q40302272 | ||
| 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth | Q40355484 | ||
| Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma | Q40367460 | ||
| Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells | Q40382287 | ||
| The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation | Q40414519 | ||
| Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation | Q40416189 | ||
| Biological effects of cosmetic talc | Q40564777 | ||
| Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene | Q41525509 | ||
| Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer | Q42626935 | ||
| Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity | Q43144666 | ||
| Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. | Q43165679 | ||
| Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells | Q43589705 | ||
| Parity, age at first childbirth, and risk of ovarian cancer | Q43706332 | ||
| Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study | Q43793343 | ||
| NFKB1Insertion/Deletion Promoter Polymorphism Increases the Risk of Advanced Ovarian Cancer in a Chinese Population | Q44335509 | ||
| HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group | Q44695868 | ||
| The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. | Q53646174 | ||
| Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer | Q54464932 | ||
| Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer | Q56786153 | ||
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 | ||
| Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes | Q57220166 | ||
| Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation | Q57250729 | ||
| Breastfeeding and risk of epithelial ovarian cancer | Q57742769 | ||
| Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients | Q57975533 | ||
| Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study | Q58352138 | ||
| Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma | Q61626123 | ||
| Pelvic inflammatory disease and the risk of epithelial ovarian cancer | Q71719886 | ||
| Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer | Q72313726 | ||
| Cancer of the ovary | Q72356478 | ||
| Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers | Q73347617 | ||
| Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel | Q73591041 | ||
| Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative tre | Q73877500 | ||
| mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool | Q74455518 | ||
| Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides | Q77738182 | ||
| Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells | Q77948519 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients | Q79399740 | ||
| Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) | Q80037226 | ||
| The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function | Q80093598 | ||
| Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer | Q80233809 | ||
| Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas | Q81346277 | ||
| Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma | Q81348863 | ||
| A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer | Q81604925 | ||
| Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients | Q81753024 | ||
| Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma | Q83336421 | ||
| Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types | Q83855414 | ||
| Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group | Q84512650 | ||
| [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer] | Q84572174 | ||
| A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer | Q87356244 | ||
| Tumor immune escape mediated by indoleamine 2,3-dioxygenase | Q36888330 | ||
| IDO activates regulatory T cells and blocks their conversion into Th17-like T cells | Q36914732 | ||
| Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 | ||
| MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. | Q37030117 | ||
| Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy | Q37040655 | ||
| Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity | Q37073953 | ||
| The NKG2D receptor: sensing stressed cells | Q37114347 | ||
| Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines | Q37140636 | ||
| Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. | Q37178234 | ||
| The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells | Q37186494 | ||
| Role of p53 and Rb in ovarian cancer | Q37188853 | ||
| Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology | Q37257207 | ||
| The MUC gene family: their role in the diagnosis and prognosis of gastric cancer | Q37284927 | ||
| Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies | Q37296509 | ||
| The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. | Q37308863 | ||
| Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. | Q37342848 | ||
| An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. | Q37348411 | ||
| Indoleamine 2,3-dioxygenase: is it an immune suppressor? | Q37362632 | ||
| Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells | Q37366455 | ||
| Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer | Q37369840 | ||
| Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors | Q37412304 | ||
| Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. | Q37415468 | ||
| Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 | Q37624504 | ||
| CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. | Q37649217 | ||
| Farletuzumab in epithelial ovarian carcinoma | Q37679219 | ||
| Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome | Q37725393 | ||
| Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response | Q37730044 | ||
| Pertuzumab for the treatment of ovarian cancer. | Q37750891 | ||
| Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. | Q37758250 | ||
| Perineal talc use and ovarian cancer risk: a case study of scientific standards in environmental epidemiology | Q37895441 | ||
| Interleukin-6 signaling pathway in targeted therapy for cancer | Q38014987 | ||
| Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | Q38419271 | ||
| A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors | Q39021494 | ||
| Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer | Q34396474 | ||
| Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay | Q34399808 | ||
| MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. | Q34423709 | ||
| Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. | Q34446318 | ||
| Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk | Q34453715 | ||
| Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas | Q34469452 | ||
| Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells | Q34486854 | ||
| Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype | Q34508811 | ||
| Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons | Q34544373 | ||
| Tumor necrosis factor or tumor promoting factor? | Q34568701 | ||
| Inherited variants in regulatory T cell genes and outcome of ovarian cancer | Q34575290 | ||
| Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma | Q34614377 | ||
| Current management strategies for ovarian cancer | Q34634661 | ||
| A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. | Q34768457 | ||
| NKG2D ligands: key targets of the immune response. | Q34792486 | ||
| Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers | Q34801008 | ||
| Circulating inflammation markers and risk of epithelial ovarian cancer | Q34949061 | ||
| Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients | Q34959906 | ||
| Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments | Q34983123 | ||
| Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer | Q35032491 | ||
| Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody | Q35036388 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 53-74 | |
| P577 | publication date | 2015-03-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P5824 | retracted by | Retraction Note: Targeted immune therapy of ovarian cancer | Q42364877 |
| P1476 | title | Targeted immune therapy of ovarian cancer | |
| P478 | volume | 34 |
| Q55044842 | Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: A preliminary study. |
| Q52686439 | Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo |
| Q122202402 | Fraxetin suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway |
| Q38787389 | High Expression of Cullin7 Correlates with Unfavorable Prognosis in Epithelial Ovarian Cancer Patients |
| Q112644363 | Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer |
| Q35741180 | Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma |
| Q57483611 | Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway |
| Q38755963 | Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma |
| Q39190035 | Nanoparticles for tumor immunotherapy |
| Q33754724 | Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients |
| Q35769650 | Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer |
| Q38696761 | Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells |
| Q37060817 | Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer |
| Q91484566 | Recent advances in applying nanotechnologies for cancer immunotherapy |
| Q42364877 | Retraction Note: Targeted immune therapy of ovarian cancer |
| Q37738040 | Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies. |
| Q45711840 | Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report |
| Q90650349 | TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model |
| Q38713749 | The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells |
| Q51533387 | UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy |
| Q58746739 | Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy |
| Q92649965 | lncRNA mortal obligate RNA transcript was downregulated in ovarian carcinoma and inhibits cancer cell proliferation by downregulating miRNA-21 |
| Q41616661 | microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer |
| Q42364877 | Retraction Note: Targeted immune therapy of ovarian cancer | main subject | P921 |
Search more.